Qu Zhang
Scientific Director, Precision Medicine Solid Tumor Abbvie
Qu is Scientific Director, Precision Medicine Solid Tumor at AbbVie, a role held since February 2024. Previously Qu worked at GSK as Director, Clinical Biomarkers in Immuno-Oncology, at Bristol Myers Squibb as Senior Principal Scientist, at AstraZeneca/MedImmune as Senior Scientist, and at Seagen as Senior Scientist. Qu holds a PhD in Bioinformatics/Evolutionary Genomics and a Master’s in Statistics from Harvard University, and a BS in Biological Sciences from the University of Science and Technology of China.
Seminars
Thursday 18th March 2027
Longitudinal Molecular Response Monitoring with ctDNA in ADC-Treated Solid Tumors
12:30 pm
- Presenting new data to track ctDNA molecular response against clinical outcome to assess how early blood-based dynamics reflect treatment benefit in patients receiving ADCs
- Examining how longitudinal monitoring performs across a pan-tumor population, highlighting where molecular response adds value beyond standard imaging
- Discusses practical implications for using molecular response to inform clinical development strategy and therapeutic decision making in ADC programs
